Bristol-Myers Squibb: Buy The Weakness

Group 1 - Bristol-Myers Squibb (BMY) is facing pressure from plans to reduce U.S. drug prices, which is seen as a significant risk for the company [2] - The company has a long position in its own shares, indicating confidence in its stock performance despite external pressures [3] - The Value Portfolio focuses on building retirement portfolios through a fact-based research strategy, which includes analyzing 10Ks, market reports, and investor presentations [2] Group 2 - The political pressure regarding drug pricing is increasing, which could impact the pharmaceutical industry significantly [2]